Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

March 31, 2013

Conditions
Cutaneous LupusDiscoid LupusLupusSystemic Lupus Erythematosus
Interventions
DRUG

AMG811

Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.

DRUG

AMG811 Placebo

8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection

Trial Locations (8)

19104

Research Site, Philadelphia

27710

Research Site, Durham

30322

Research Site, Atlanta

48103

Research Site, Ann Arbor

75231

Research Site, Dallas

84107

Research Site, Salt Lake City

90404

Research Site, Santa Monica

94305

Research Site, Stanford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY